About Us

Company Overview

OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization expertise to pursue acquisitions of commercial businesses that will both drive our growth and provide geographically diverse sales and distribution opportunities. We have and may continue to make investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.

Our Focus

Recent Highlights

Since 2009, OPKO has completed national and international acquisitions of the following companies:

  • OURLabs, acquired by OPKO in December 2012, includes urologic, gastrointestinologic, dermapathologic, and women’s health laboratories based in Nashville, Tennessee. OURLabs operates 18 phlebotomy sites throughout the United States and is strategically positioned as OPKO’s commercial platform for the anticipated U.S. launch of 4Kscore™, a prostate cancer biomarker panel.
  • OPKO Diagnostics creates innovative point-of-care diagnostics technology that transition in-vitro medical diagnostics tests from the laboratory to the physician’s office and allow the performance of complex laboratory quality assays in minutes with no training and at minimal cost.
  • OPKO Chile markets, sells, and distributes pharmaceutical and nutraceutical products to private, hospital, and institutional markets in Chile.
  • OPKO EU develops, manufactures, markets, and sells a line of pharmaceutical, nutraceutical, and veterinary products throughout Europe.
  • OPKO FineTech develops specialty active pharmaceutical ingredients (APIs) in Israel.
  • OPKO Mexico manufactures, markets, sells, and distributes ophthalmic and other pharmaceutical products to private and public customers in Mexico.

OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.




Strategic Investments

  • OPKO Chile
    Acquired: Pharma Genexx (October 2009) Acquired: ALS Distribuidora Limitada (April 2012)
    Acquired: Farmadiet (August 2012)
  • OPKO FineTech
    Acquired: December 2011
  • OPKO Mexico
    Acquired: Pharma Exakta (February 2010)


  • OPKO Diagnostics Acquired: Claros Diagnostics (October 2011)
  • OURLabs
    Acquired: December 2012
  • Molecular Diagnostics


    Acquired: February 2011
  • Biozone Pharmaceuticals
  • Cocrystal Discovery, Inc.
  • Fabrus, Inc.
  • Neovasc, Inc.
  • Sorrento Therapeutics, Inc.
  • TESARO, Inc.

Experienced Management Team:

OPKO has a highly experienced management team that we believe has demonstrated an ability to successfully build and manage pharmaceutical businesses. Our Chairman and Chief Executive Officer, Dr. Phillip Frost, founded and served as Chairman and Chief Executive Officer of IVAX Corporation, a multi-national pharmaceutical company, from 1987 until the acquisition of IVAX by Teva Pharmaceutical Industries, Limited in January 2006. Dr. Frost currently serves as Chairman of the Board of Teva. Prior to Ivax, Dr. Frost founded and served as Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Our other senior executive officers are also veterans in the pharmaceutical industry and have extensive development, regulatory, and commercialization expertise.

It is our conviction that OPKO’s experienced management team has the development, regulatory, and commercialization expertise and relationships able to access and facilitate excellent commercial opportunities.